Results 161 to 170 of about 1,718 (175)

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs

Pharmacology Research and Perspectives, 2018
Agnes Poirier, Mohammed Ullah, Hasane Ratni   +2 more
exaly  

Nusinersen/Risdiplam

Reactions Weekly
openaire   +1 more source

Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy

New England Journal of Medicine
Richard S, Finkel, Samuel H, Hughes, JulieAnn, Parker, Matthew, Civitello, Alfonso, Lavado, Heather C, Mefford, Lutz, Mueller, Heidemarie, Kletzl   +7 more
openaire   +2 more sources

An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies

European Journal of Paediatric Neurology
Doris Giess
exaly  

A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy

Muscle and Nerve
Jeffrey C Powell, James B Meiling, Michael S Cartwright   +2 more
exaly  

In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.

The Medical letter on drugs and therapeutics, 2021
openaire   +1 more source

Orphan designation: Risdiplam, Treatment of spinal muscular atrophy

Case Medical Research, 2019
openaire   +2 more sources

Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy

New England Journal of Medicine
Renske I, Wadman, Ewout J N, Groen, W Ludo, van der Pol   +2 more
openaire   +4 more sources

Risdiplam in Adult Patients With 5q Spinal Muscular Atrophy: A Single‐Center Longitudinal Study

Muscle and Nerve
Maria Gavriilaki, Marianthi Arnaoutoglou, Vasilios K Kimiskidis   +2 more
exaly  

Safety of risdiplam in spinal muscular atrophy patients after short‐term treatment with nusinersen

Muscle and Nerve
Yijie Feng, Liya Jiang, Jianing Jin
exaly